Abstract
Because the affected parts of some tumors and diseases are generally hidden, some are deeper, and the tissue structure is more complex and diverse, misdiagnosis and missed diagnosis are very easy to occur in the process of clinical diagnosis. In addition, the development of various diseases and tumors is closely related to the quality of life and prognosis of patients. Therefore, the diagnosis and treatment of diseases and monitoring after treatment are particularly important for patients. Ultrasound is easy to operate, non-invasive, and can be observed in real time. Ultrasound is the most used Frequent imaging diagnostic tools. In recent years, contrast-enhanced ultrasound (CEUS), as a newly developed imaging technology, has made important progress in ultrasound examination. In particular, the second-generation microbubble (MB) contrast agent in contrast-enhanced ultrasound (CEUS) has been widely used in clinical practice. It can observe the whole process of organ and tumor microcirculation blood perfusion in real time and continuously, not only The morphological characteristics of the lesion can also provide the blood flow characteristics of the lesion, which improves the ability of the ultrasonic diagnostic instrument to display the blood flow in the lesion. Due to its non-invasiveness, real-time and safety, contrast-enhanced ultrasound technology provides safe, effective and valuable diagnostic and treatment options for ophthalmology, liver, gastrointestinal tract, heart, pediatrics and other fields. This article briefly reviews the origin and development of contrast agent ultrasound, basic principles, safety, the application of contrast-enhanced ultrasound in clinical diagnosis and treatment, and the advantages and disadvantages of contrast-enhanced ultrasound, and discusses its future development and limitations for pre-clinical surgery The qualitative diagnosis, selection of surgical methods and prognostic judgment and evaluation provide more accurate and comprehensive information in order to better serve and treat clinical diagnosis.
Highlights
The discovery of contrast-enhanced ultrasound (CEUS) can be traced back to 1968
Migaleddu et al found that CEUS is evaluating the inflammatory activity of 47 CD patients, and found that CEUS has high sensitivity and specificity in detecting inflammatory activity based on the Crohn’s Disease Activity Index (CDAI) score
There is supervision when using ultrasound contrast agents (UCA) for contrast-enhanced ultrasound, But a lot of evidence shows that CEUS can provide unique and accurate diagnostic information
Summary
The discovery of contrast-enhanced ultrasound (CEUS) can be traced back to 1968. After Gramiak and Shah injected normal saline through the intra-aortic catheter, a "bubble cloud" appeared in the aortic root. The discovery and practicability of the first generation of UCA led to the rapid development of CEUS. Sidhu PS et al published the 2017 updated version of the European Federation of Medical and Biological Ultrasound Societies (EFSUMB) practice guidelines for the use of CEUS in non-liver applications. In these guidelines, EFSUMB proposed to use CEUS for pancreatic masses, endoscopic ultrasound examination, gastrointestinal tract, spleen, genitourinary system assessment, etc., and continue to improve and promote the development of CEUS [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
